Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-CV phase 3 trial of maridebart cafraglutide in ASCVD with overweight or obesity
CTR20253681Phase 3Active
- Sponsor
- Amgen
- Start
- Nov 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of maridebart cafraglutide in atherosclerotic disease, Overweight, obesity, sponsored by Amgen. Started Nov 2025; status: active.
02
Drugs
maridebart cafraglutide
03
Conditions
atherosclerotic diseaseOverweightobesity
Beyond the preview
Go deeper on CTR20253681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253681.